Favorable phase II data with N-methyl-D-aspartate (NMDA) receptor antagonist AXS-05 sent Axsome Therapeutics Inc.'s shares skyrocketing more than 200 percent on Monday, and offered new hope for an estimated 16 million major depressive disorder (MDD) patients in the U.S.